Src family kinase inhibitor PP2 has different effects on all-trans-retinoic acid or arsenic trioxide-induced differentiation of an acute promyelocytic leukemia cell line

Cancer Research and Treatment

Volumn 45, Issue 2, 2013, Pages 126-133

  Yoon, Suk Gu ^a   Cheong, Hee Jeong ^a   Kim, Sook Ja ^a   Kim, Kyoung Ha ^a   Lee, Sang Cheol ^a   Lee, Namsu ^a   Park, Hee Sook ^a   Won, Jong Ho ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Cell differentiation; Src kinase

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ARSENIC TRIOXIDE; CATHEPSIN D; CD11B ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN TYROSINE KINASE; RETINOIC ACID;

APOPTOSIS; ARTICLE; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE; LEUKEMIA CELL LINE; PROMYELOCYTIC LEUKEMIA; TUMOR DIFFERENTIATION;

EID: 84886299893     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.45.2.126     Document Type: Article

References (22)

1. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 2009;335:249-59.
2. Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem. 2010;285:21446-57.
3. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996;56:3589-96.
4. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 2002;21:5766-74.
5. Chen Y. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias? Leuk Res. 2011;35:27-9.
6. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood. 2008;111:2269-79.
7. Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010;24:663-5.
8. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010;16:1149-58.
9. Mermel CH, McLemore ML, Liu F, Pereira S, Woloszynek J, Lowell CA, et al. Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood. 2006;108:2562-8.
10. Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity. 2001;15:603-15.
11. Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther. 2007;6(12 Pt 1):3081-90.
12. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505-15.
13. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114:5126-35.
14. Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia. 2007;21:1363-77.
15. Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood. 1999;93:1-14.
16. Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia. 2012;26:1180-8.
17. Park KB, Hong DS, Suh WS, Lee NS, Park SG, Won JH, et al. Arsenic trioxide (As2O3) induced apoptosis in NB4 cell lines. Korean J Hematol. 2002;37:200-11.
18. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-8.
19. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14:262-70.
20. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-meth-ylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-61.
21. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328-35.
22. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469-73.